CNX acquires four cancer drugs from Clinigen
The purchased therapies concerned are Cardioxane, Totect, Ethyol and Savene
Read More
Tag: Clinigen
Clinigen’s ALS therapy bags US orphan status
Clinigen has bagged a US orphan drug designation (ODD) for its investigational Amyotrophic Lateral Sclerosis (ALS) treatment aldesleukin.
Read More
Clinigen launches programme to provide Azedra outside US
The Progenics drug is currently not approved for any indication outside of the US.
Read More
Clinigen buys global rights to Horizon’s Imukin
The UK’s Clinigen Group has bought global rights to rare disease therapy Imukin from Horizon Pharma, for an undisclosed amount.
Read More
Clinigen, Mitsubishi link for early access programme
Clinigen says it has partnered with Mitsubishi Tanabe Pharma to initiate a Managed Access Program in Europe for edaravone, an intravenous treatment for amyotrophic lateral sclerosis (ALS).
Read More
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
